TCF12 Antibody

What is TCF12 and what are its primary functions in cellular processes?

TCF12 (Transcription factor 12), also known as HTF4 or HEB, is a member of the helix-loop-helix (HLH) protein family. It functions as a transcriptional regulator that plays crucial roles in cell development and differentiation across various tissues, including skeletal muscle, neurons, mesenchymal tissues, and lymphocytes. TCF12 activates transcription by binding to E-box sequences (5'-CANNTG-3') in the promoter regions of target genes. It can form homodimers or heterodimers with other HLH family members to regulate gene expression . Recent studies have revealed its involvement in neuronal differentiation, hematopoietic stem cell function, muscle development, and cancer progression .

What are the molecular characteristics of TCF12 protein that researchers should be aware of?

TCF12 has a calculated molecular weight of 73 kDa, although it may appear at approximately 80-85 kDa in Western blot analyses due to post-translational modifications . The protein contains critical functional domains including the bHLH (basic helix-loop-helix) domain that mediates DNA binding and protein-protein interactions. When selecting antibodies, researchers should consider that different isoforms exist, and antibodies targeting different epitopes may yield varying results. The human TCF12 gene is located on chromosome 15, and its protein product contains conserved regions that show high homology across species including human, mouse, and rat .

How is TCF12 implicated in disease states based on current research?

Research indicates that TCF12 has significant roles in multiple pathological conditions:

What are the optimal conditions for using TCF12 antibodies in Western blotting?

Western blotting for TCF12 requires careful optimization to ensure specific detection. Based on validated protocols, the following parameters are recommended:

• Dilution range: 1:1000-1:10000 for most commercial antibodies

• Protein loading: 5-50 µg of whole cell lysate, depending on expression level

• Detection methods: ECL technique works effectively with exposure times of 2-3 minutes

• Expected band size: Primary band at ~73 kDa, though observed at ~80-85 kDa in many cell lines

• Buffer systems: Most antibodies perform well with standard PVDF membranes and reducing conditions

• Positive controls: HeLa, Jurkat, HepG2, and Raji cells consistently show strong TCF12 expression

For optimal results, researchers should perform a titration experiment with their specific sample type, as TCF12 expression varies considerably between different tissues and cell lines.

What considerations are important when designing ChIP-seq experiments with TCF12 antibodies?

ChIP-seq for TCF12 requires special considerations based on published successful protocols:

• Cell fixation: 1% PFA for 10 minutes at room temperature, followed by quenching with 125 mM glycine

• Cell number requirements: Approximately 4×10^6 cells for TCF12 IP and 1×10^6 cells for histone mark controls

• Antibody selection: Choose antibodies validated specifically for ChIP applications with published ChIP-seq data

• Controls: Include:

  • Input chromatin (pre-IP sample)

  • IgG control to determine non-specific binding

  • Histone mark controls (H3K27Ac, H3K4me3) to identify active regulatory regions

• Data analysis: E-box motif analysis is essential, with particular focus on CANNTG sequences and their flanking regions

• Cross-validation: Validate ChIP-seq findings with gene expression data following TCF12 knockdown or overexpression

How should researchers approach TCF12 immunohistochemistry in different tissue samples?

Successful immunohistochemistry for TCF12 requires tissue-specific optimization:

• Fixation: Formalin-fixed paraffin-embedded (FFPE) tissues are commonly used

• Antigen retrieval: Two methods have proven effective:

  • TE buffer (pH 9.0) - preferred method for most tissues

  • Citrate buffer (pH 6.0) - alternative method that may work better for certain tissues

• Antibody dilution: 1:50-1:500 range, requiring optimization for each tissue type

• Detection systems: Both chromogenic and fluorescent detection systems are compatible

• Positive controls:

  • Human cervical cancer tissue has been validated for many commercial antibodies

  • Melanoma tissue shows strong expression in advanced/metastatic cases

• Counterstaining: Hematoxylin for nuclear visualization, as TCF12 shows predominantly nuclear localization

Troubleshooting TCF12 Antibody Applications

Comprehensive validation is critical for ensuring reliable TCF12 detection:

• Genetic validation:

  • Use CRISPR/Cas9 TCF12 knockout cells as negative controls

  • Compare with TCF12 knockdown samples (siRNA or shRNA)

  • Overexpression systems to confirm band mobility

• Epitope competition:

  • Pre-incubate antibody with immunizing peptide (if available)

  • Observe elimination of specific signal

• Orthogonal validation:

  • Compare results from multiple antibodies targeting different TCF12 epitopes

  • Correlate protein detection with mRNA expression data

• Technical controls:

  • Include positive control cell lines with known TCF12 expression (HepG2, Jurkat, Raji)

  • Use molecular weight markers to confirm band size

How can conflicting results between different TCF12 antibodies be resolved?

When researchers encounter discrepancies between different TCF12 antibodies:

• Epitope mapping:

  • Determine which domain each antibody recognizes (N-terminal, bHLH domain, C-terminal)

  • Antibodies targeting different domains may detect different isoforms or conformations

• Application-specific validation:

  • An antibody working well for WB may not be suitable for IHC or ChIP

  • Perform application-specific validation for each antibody

• Context-dependent expression:

  • TCF12 forms different protein complexes in different cell types

  • Post-translational modifications may affect epitope accessibility

• Cross-reactivity assessment:

  • Test for cross-reactivity with other E-proteins (TCF3, TCF4)

  • Sequence alignment analysis to identify potential cross-reactive epitopes

• Reconciliation approach:

  • Use complementary detection methods (e.g., mass spectrometry)

  • Perform RNA-seq to correlate with protein results

  • Employ genetic models (knockout/knockdown) to validate specificity

How can TCF12 antibodies be utilized to investigate its role in transcriptional complexes?

Investigating TCF12's interactions with other transcription factors requires sophisticated approaches:

• Sequential ChIP (ChIP-reChIP):

  • First ChIP with TCF12 antibody, followed by a second IP with antibodies against potential partners

  • Identifies genomic regions co-occupied by TCF12 and partner proteins

  • Successfully used to identify TCF12:PGC1α interactions in melanoma

• Co-immunoprecipitation (Co-IP) strategies:

  • Reciprocal Co-IP using TCF12 antibody and antibodies against potential partners

  • Effective for detecting TCF12:TCF4 heterodimer formation in glioblastoma cells

  • Buffer optimization crucial for maintaining complex integrity

• Proximity ligation assays (PLA):

  • Visualizes TCF12 protein-protein interactions in situ

  • Provides spatial information about interaction sites within the cell

• RIME (Rapid Immunoprecipitation Mass spectrometry of Endogenous proteins):

  • Combines IP with mass spectrometry to identify TCF12-interacting proteins

  • Useful for discovering novel interaction partners

• DNA-protein interaction analysis:

  • Electrophoretic mobility shift assays (EMSA) with supershift using TCF12 antibodies

  • Used to demonstrate TCF12:TCF4 binding to specific E-box sequences

What are the most effective approaches for studying TCF12's role in chromatin remodeling and epigenetic regulation?

Recent studies have revealed TCF12's involvement in chromatin-level regulation:

• Integrated ChIP-seq analysis:

  • Parallel ChIP-seq for TCF12 and histone modifications (H3K27ac, H3K4me3, H3K27me3)

  • Correlation analysis to identify TCF12's association with active/repressive chromatin states

  • Integration with ATAC-seq data to assess chromatin accessibility at TCF12 binding sites

• ChIP-seq followed by motif analysis:

  • Identify enriched E-box motifs (CANNTG) and variations

  • Analysis of flanking sequences that may determine dimer-specific binding

  • Comparison between different cell types to identify context-specific binding patterns

• Investigation of TCF12's interaction with chromatin modifiers:

  • Co-IP with histone modifying enzymes (HDACs, HATs, HMTs)

  • Sequential ChIP to detect co-occupancy of TCF12 with chromatin modifiers

  • Functional studies combining TCF12 knockdown with epigenetic inhibitors

• CUT&RUN or CUT&Tag as alternatives to ChIP:

  • Higher resolution and lower background than traditional ChIP

  • Requires less starting material and has higher signal-to-noise ratio

  • Can be combined with single-cell approaches for heterogeneity analysis

How can researchers utilize TCF12 antibodies to understand its dual functions in both oncogenic and tumor-suppressive contexts?

TCF12 exhibits context-dependent functions that require careful experimental design:

• Context-specific protein complex identification:

  • Differential interactome analysis in cancer vs. normal cells

  • Comparison between contexts where TCF12 is oncogenic (melanoma) vs. tumor-suppressive (as TCF4:TCF12 in glioblastoma)

  • Mass spectrometry following TCF12 IP to identify context-specific binding partners

• Target gene regulation analysis:

  • ChIP-seq in multiple cancer types to compare binding patterns

  • Integration with transcriptomic data from TCF12 perturbation experiments

  • Focus on known TCF12 targets like TGFB2 in melanoma and POSTN in glioblastoma

• Dimer-specific functions:

  • Use of tethered dimers (e.g., TCF12:TCF12 homodimers vs. TCF12:TCF4 heterodimers)

  • Comparison of genomic binding sites and transcriptional effects

  • Development of dimer-specific antibodies or proximity-based detection methods

• Post-translational modification analysis:

  • IP followed by mass spectrometry to identify cancer-specific modifications

  • Phospho-specific antibodies to detect activation states

  • Correlation of modifications with functional outcomes

• In vivo modeling using genetic approaches:

  • TCF12 conditional knockout in specific tissues using Cre-lox systems

  • Rescue experiments with wild-type vs. mutant TCF12

  • Comparison with human tumor samples using IHC to validate findings

How can single-cell approaches be combined with TCF12 antibodies to understand cellular heterogeneity?

Emerging single-cell technologies offer new insights into TCF12 function:

• Single-cell Western blotting:

  • Quantifies TCF12 protein levels in individual cells

  • Reveals population heterogeneity masked in bulk analyses

  • Can be combined with co-detection of interaction partners

• CyTOF (mass cytometry):

  • Multiplexed detection of TCF12 alongside other proteins and phosphorylation sites

  • Enables high-dimensional analysis of signaling networks

  • Useful for analyzing rare cell populations in heterogeneous tissues

• Single-cell CUT&Tag:

  • Maps TCF12 binding sites at single-cell resolution

  • Reveals cell-to-cell variability in genomic targeting

  • Can be integrated with single-cell RNA-seq data

• smFISH combined with immunofluorescence:

  • Correlates TCF12 protein levels with target gene mRNA expression at single-cell level

  • Provides spatial information within tissues or tumor microenvironments

• CODEX multiplexed imaging:

  • Simultaneous visualization of TCF12 with dozens of other proteins

  • Preserves tissue architecture and cellular relationships

  • Particularly valuable for understanding TCF12 function in complex tissues

What methodological approaches should be considered when studying TCF12 in primary patient samples versus cell lines?

Working with clinical samples presents unique challenges:

Specific recommendations for primary samples:

• Tissue microarrays enable screening multiple patient samples with standardized conditions

• Multiplex IHC/IF provides contextual information about TCF12 expression relative to other markers

• Laser capture microdissection can isolate specific cell populations for more focused analysis

• Fresh frozen samples generally yield better results than FFPE for certain applications

• Correlation with patient metadata (clinical outcomes, molecular subtypes) adds valuable clinical relevance

How might TCF12 antibodies be used in therapeutic development research?

Although primarily research tools, TCF12 antibodies contribute to therapeutic discovery:

• Target validation:

  • Confirm TCF12's role in disease models before therapeutic development

  • Evaluate expression patterns across patient samples using IHC

  • Correlate with response to existing therapies (e.g., BRAF inhibitors in melanoma)

• Mechanism-of-action studies:

  • Monitor changes in TCF12 expression, localization, or complex formation in response to drug candidates

  • ChIP-seq to detect alterations in genomic binding after treatment

  • IP-MS to identify changes in interactome following therapy

• Companion diagnostic development:

  • IHC protocols could be adapted for patient stratification

  • Identify patients most likely to benefit from TCF12-targeting approaches

  • Develop scoring systems based on expression level or subcellular localization

• Therapeutic monoclonal antibody development:

  • Research-grade antibodies inform epitope selection

  • Internalization assays to evaluate potential for antibody-drug conjugates

  • Functional screening to identify antibodies that disrupt specific interactions

• Monitoring treatment effects:

  • Evaluate changes in TCF12 target genes (TGFB2, POSTN) following therapy

  • Assess pathway modulation through downstream signaling analysis

  • Analyze treatment-resistant populations for TCF12-related mechanisms